The role of istradefylline in the Parkinson's disease armamentarium.

receptor occurs and weakens the efficacy of istradefylline as modulator of dopamine effects on motor behaviour in Parkinson's disease. This is the still hypothetical reason, why clinical trials failed, when patients were on a higher chronic levodopa regimen.A way out of this dilemma is to enable higher dosing of istradefylline and substitution of L-dopa with compounds, which do not influence the methylation capacity. Long term trials may show these levodopa sparing and thus motor complications delaying effects of istradefylline.